|Bid||1,442.20 x 0|
|Ask||1,443.20 x 0|
|Day's range||1,422.40 - 1,486.20|
|52-week range||1,190.80 - 1,528.80|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||16.62|
|Earnings date||27 Oct 2021|
|Forward dividend & yield||0.80 (5.62%)|
|Ex-dividend date||19 Aug 2021|
|1y target est||1,584.17|
Group turnover was up by 5% to £9.07bn.
The company revealed that turnover grew by 5% to £9.1 billion in the third quarter, surpassing an analyst consensus of around £8.7 billion.
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.